Search

Search Constraints

You searched for: Author/Creator Kazandjian, Dickran

Search Results

1. A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma. Issue 1 (20th November 2017)

3. Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. (10th March 2021)

4. Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma. (10th March 2021)

7. Clinician Perspectives on Current Issues in Lung Cancer Drug Development. Issue 9 (September 2016)

8. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. (November 2018)

9. Diagnostic performance of 18F‐FDG‐PET/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward. (23rd September 2020)

10. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Issue 10 (24th August 2022)